Biophytis is a biotechnology business based in the US. Biophytis stocks (BPTS.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $11.435 – a decrease of 12.12% over the previous week. Biophytis employs 26 staff and has a market cap (total outstanding stock value) of $21.2 million.
How to buy stocks in Biophytis
- Compare stock trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – BPTS – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of stocks with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Finder's Pick for
Beginners

Finder's Pick for
Free Trades

Finder's Pick for
Commodity Stocks

Finder's Pick for
Global Trading

Biophytis stock price (NASDAQ:BPTS)
Use our graph to track the performance of BPTS stocks over time.Biophytis shares at a glance
Latest market close | $1.16 |
---|---|
52-week range | $1.00 - $13.17 |
50-day moving average | $2.06 |
200-day moving average | $5.16 |
Wall St. target price | $15.00 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-2.79 |
Compare stock trading platforms
Note: The dollar amounts in the table below are in Canadian dollars.
Is it a good time to buy Biophytis stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Biophytis price performance over time
Historical closes compared with the close of $1.16 from 2022-05-20
1 week (2022-05-13) | -22.67% |
---|---|
1 month (2022-04-22) | -38.30% |
3 months (2022-02-23) | -69.37% |
6 months (2021-11-23) | -77.25% |
1 year (2021-05-21) | -90.00% |
---|---|
2 years (2020-05-19) | N/A |
3 years (2019-05-19) | N/A |
5 years (2017-05-19) | N/A |
Biophytis financials
Gross profit TTM | $0 |
---|---|
Return on assets TTM | -52.81% |
Return on equity TTM | -783.82% |
Profit margin | 0% |
Book value | $0.42 |
Market capitalisation | $21.2 million |
TTM: trailing 12 months
Biophytis share dividends
We're not expecting Biophytis to pay a dividend over the next 12 months.
Biophytis share price volatility
Over the last 12 months, Biophytis's shares have ranged in value from as little as $0.9988 up to $13.17. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Biophytis's is 1.4195. This would suggest that Biophytis's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Biophytis overview
Biophytis S. A. , a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD.
Biophytis in the news

SEC filings reveal massive selling in media names, including Disney and Comcast

Biophytis: Biophytis Announces its Participation at the BIO International Convention in San Diego from the 13th to the 16th of June

Cable companies to offer effectively free internet to low-income homes
Frequently asked questions
Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.
More on investing

Online gaming stocks
iGaming is now legal in Ontario. Find out which companies to keep an eye on with our list of 10 top online gaming stocks.
Read more…
Best brokerage signup bonuses in 2022
Enjoy perks like free trades and cash rewards when you open a stock trading account with these online brokers.
Read more…
Popular propane stocks to buy in Canada
Here’s what you need to know about investing in the propane industry, including 3 popular propane stocks to watch.
Read more…More guides on Finder
-
Apps like Wealthsimple
Learn more about apps like Wealthsimple to find the best trading platform for your unique set of needs.
-
Online gaming stocks
iGaming is now legal in Ontario. Find out which companies to keep an eye on with our list of 10 top online gaming stocks.
-
How to buy Entain stock in Canada
Steps to owning and managing ENT stock, with 24-hour and historical pricing before you buy.
-
How to buy Kambi Group stock in Canada
Steps to owning and managing KAMBI stock, with 24-hour and historical pricing before you buy.
-
Best brokerage signup bonuses in 2022
Enjoy perks like free trades and cash rewards when you open a stock trading account with these online brokers.
-
How to buy Rush Street Interactive stock in Canada
Steps to owning and managing RSI stock, with 24-hour and historical pricing before you buy.
-
How to buy PointsBet stock in Canada
Steps to owning and managing PBTHF stock, with 24-hour and historical pricing before you buy.
-
How to buy Hanover Bancorp, Inc. (HNVR) stock in Canada when it goes public
Everything we know about the Hanover Bancorp, Inc. IPO, plus information on how to buy in.
-
How to buy PrimeBlock stock in Canada when it goes public
Everything we know about the PrimeBlock IPO, plus information on how to buy in.
-
How to buy Actelis Networks (ASNS) stock in Canada when it goes public
Everything we know about the Actelis Networks IPO, plus information on how to buy in.